Loading clinical trials...

Effect of Gastrectomy and Anastomosis on Diabetes and Hypertension in Early Gastric Cancer Patients | Clinical Trials | Clareo Health

COMPLETED

Effect of Gastrectomy and Anastomosis on Diabetes and Hypertension in Early Gastric Cancer Patients

Effect of Gastrectomy and Anastomosis on Chronic Metabolic Disease Such as Diabetes and Hypertension in Early Gastric Cancer Patients

NCT01643811•National Cancer Center, Korea

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether the extent of gastrectomy and anastomosis type affect chronic metabolic disease such as diabetes and hypertension in early gastric cancer patients.

Eligibility

Age

20 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologically proven primary gastric adenocarcinoma
•clinical stage Ia or Ib examined with endoscopy, endoscopic ultrasound, and computed tomography
•aged 20-80 year old,
•performance status (PS) of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale
•diagnosed as diabetes or hypertension
•patients planning to undergo gastrectomy or endoscopic submucosal dissection
•written informed consent

Exclusion Criteria

•having high risk for operation such as severe heart disease, severe respiratory disease
•pregnant
•previous abdominal surgery or radiation therapy
•proven more advanced disease than pathological stage II requiring adjuvant chemotherapy

Locations (1)

National Cancer Center

Goyang, Kyeonggi-do, South Korea

Key Dates

Start Date

April 1, 2012

Primary Completion Date

February 1, 2016

Completion Date

February 1, 2016

Last Updated

March 24, 2016

Enrollment

159

ACTUAL participants

Conditions

Early Gastric Cancer

Interventions

gastrectomy

PROCEDURE

Endoscopic submucosal dissection

PROCEDURE

Clinical Application of Genetic Sequencing of Early Gastric Cancer and Gastric Adenoma Patients

NCT04665687

Early Gastric CancerGastric Adenoma

View study

RECRUITING

Multimodal Deep Learning for Lymph Node Metastasis Prediction and Physician Performance Assessment in T1 Gastric Cancer

NCT07124754

T1 Gastric Cancer Lymph Node Metastasis Early Gastric Cancer Artificial Intelligence-Assisted Diagnosis Multimodal Data Integration

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 24, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect of Gastrectomy and Anastomosis on Diabetes and Hypertension in Early Gastric Cancer Patients

Inclusion Criteria

Exclusion Criteria

Clinical Application of Genetic Sequencing of Early Gastric Cancer and Gastric Adenoma Patients

Multimodal Deep Learning for Lymph Node Metastasis Prediction and Physician Performance Assessment in T1 Gastric Cancer

Explainable Machine Learning for Predicting Early Gastric Cancer

A Multifactor Prediction Model for Non-curative Outcomes in Mixed-type Early Gastric Cancer

A Study on the Potential Benefit of Neoadjuvant Therapy for AGC Patients

Setting the Shortest Examination Time of Gastroscopy to Improve the Detection Rate of Upper Gastrointestinal Tumors